کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3401760 | 1222682 | 2012 | 89 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012)
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
GESIDARecomendaciónEfectos adversos - اثرات جانبیAIDS - ایدزrecommendations - توصیه هاFármacos antirretrovirales - داروهای ضد رتروویروسیAntiretroviral treatment - درمان ضد رتروویروسیTratamiento antirretroviral - درمان ضد رتروویروسیGuideline - دستورالعملGUIA - راهنمایSIDA - صفحهInfección por el virus de la inmunodeficiencia humana - عفونت با ویروس نقص ایمنی بدن انسانhuman immunodeficiency virus infection - عفونت ویروس نقص ایمنی بدن انسانAdverse events - عوارض جانبی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
میکروب شناسی
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
The current antiretroviral treatment (ART) of choice for chronic HIV infection is the combination of three drugs. ART is recommended in patients with symptomatic HIV infection, in pregnancy, in serodiscordant couples with high transmission risk, hepatitis B fulfilling treatment criteria, and HIV nephropathy. Guidelines on ART treatment in patients with concurrent diagnosis of HIV infection and an opportunistic type C infection are included. In asymptomatic patients ART is recommended on the basis of CD4 lymphocyte counts, plasma viral load and patient co-morbidities, as follows: 1) therapy should be started in patients with CD4 counts <350 cells/μL; 2) when CD4 counts are between 350 and 500 cells/μL, therapy will be recommended and only delayed if patient is reluctant to take it, the CD4 are stabilised, and the plasma viral load is low; 3) therapy could be deferred when CD4 counts are above 500 cells/μL, but should be considered in cases of cirrhosis, chronic hepatitis C, high cardiovascular risk, plasma viral load >105 copies/mL, proportion of CD4 cells <14%, and in people aged >55 years. ART should include 2 reverse transcriptase inhibitors nucleoside analogues and a third drug (non-analogue reverse transcriptase inhibitor, ritonavir boosted protease inhibitor or integrase inhibitor). The panel has consensually selected and given priority to using the Gesida score for some drug combinations, some of them co-formulated. The objective of ART is to achieve an undetectable viral load. Adherence to therapy plays an essential role in maintaining antiviral response. Therapeutic options are limited after ART failures, but an undetectable viral load may be possible nowadays. Adverse events are a fading problem of ART. Guidelines in acute HIV infection, in women, in pregnancy, and to prevent mother-to-child transmission and pre- and post-exposition prophylaxis are commented upon. Management of hepatitis B or C co-infection, other co-morbidities, and the characteristics of ART in HIV-2 infection are included.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Enfermedades Infecciosas y MicrobiologÃa ClÃnica - Volume 30, Issue 6, JuneâJuly 2012, Pages e1-e89
Journal: Enfermedades Infecciosas y MicrobiologÃa ClÃnica - Volume 30, Issue 6, JuneâJuly 2012, Pages e1-e89
نویسندگان
Panel de expertos de Gesida y Plan Nacional sobre el Sida Panel de expertos de Gesida y Plan Nacional sobre el Sida,